Quantcast

Latest pulmonary fibrosis Stories

2014-09-16 20:27:17

-- Survey Data Requested by FDA for the September 26 Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis CHICAGO, Sept. 16, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced today that it has submitted survey data from more than 1,100 patients and families suffering from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis on...

2014-09-10 12:24:27

RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts: Idiopathic Pulmonary Fibrosis -- a documentary supported by the company and created in collaboration with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis in an effort to increase awareness and understanding of idiopathic pulmonary fibrosis (IPF) among the general public....

2014-09-09 08:32:06

For U.S. Media Only RIDGEFIELD, Conn., Sept. 9, 2014 /PRNewswire/ -- A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS(TM) trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib on reducing the decline in lung function, as measured by annual rate of decline in forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF)...

2014-09-02 16:25:40

Mayor Rahm Emanuel declares September Global Pulmonary Fibrosis Awareness Month in Chicago--the Pulmonary Fibrosis Foundation sponsors events to enhance disease awareness and provides patient and caregiver feedback to the FDA CHICAGO, Sept. 2, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) launches a full month of events and initiatives for September's Global Pulmonary Fibrosis (PF) Awareness Month, starting with a proclamation by Chicago's mayor; surpassing a...

2014-08-24 12:20:28

-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune's...

2014-08-14 16:27:01

New data will be reported to FDA at patient-focused drug development meeting on 9/26; insights will help future PFF programs and services CHICAGO, Aug. 14, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced that it has funded a survey designed to collect patient insights, which will help inform decision makers with a better understanding of pulmonary fibrosis (PF). The information collected will provide a better understanding of patients' and...

2014-08-05 08:34:38

MORRISTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Moerae Matrix, Inc. announced today the initiation of a Phase 1 clinical trial of MMI-0100, a first-in-class inhibitor of MAPKAP Kinase 2 (MK2) being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases characterized by inflammation and fibrosis. The Phase 1 study is being conducted in the Netherlands and will evaluate the safety, tolerability and pharmacokinetics of ascending doses of MMI-0100 when given...

2014-07-23 16:27:13

Patients, caregivers and health care professionals share stories; offer awareness, hope and inspiration CHICAGO, July 23, 2014 /PRNewswire-USNewswire/ -- Twenty of the Pulmonary Fibrosis Foundation's advocates have come together to inaugurate PFF Ambassador program, a group of idiopathic pulmonary fibrosis (IPF) patients and caregivers who are committed to share personal stories of living with IPF as well as health care providers who deliver current disease education information to...

2014-07-21 20:22:22

Nintedanib and Pirfenidone Received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) - PFF Disease Education Webinars scheduled CHICAGO, July 21, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) is pleased to announce two upcoming webinars, one of which is related to the U.S. Food and Drug Administration (FDA) granting breakthrough therapy designation for two new investigational treatments for idiopathic pulmonary fibrosis (IPF)....

2014-07-16 12:28:07

For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). The efficacy and safety of nintedanib in the treatment of IPF has not been established. "Boehringer Ingelheim is proud that...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related